|Title||Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI. (AVIATOR 2 Registry)|
|Summary||AVIATOR is an observational (no treatment) registry of patients who have atrial fibrillation (a common heart rhythm abnormality) and who are undergoing percutaneous coronary intervention (PCI) for stent placement. Participants’ treatment is observed, but is not dictated or changed by the registry. The purpose of the study is to examine patterns of anti-platelet (blood thinning) and anti-thrombotic (anti blood clot) prescribing practices and patient adherence, and to describe types of bleeding and ischemic (decreased blood flow) events that may occur following PCI.|
A registry is a collection of information about patients, usually focused around a specific diagnosis or condition. Many registries collect information about people who have a specific disease or condition. In this registry, patients who have atrial fibrillation and atrial flutter (AF) (common heart rhythm abnormalities) and who are undergoing coronary artery stent placement through a percutaneous coronary intervention (PCI) will be included. The goal of this registry is to study various combinations of anti-platelet (blood thinning) and anti-thrombotic (anti-blood clot) therapies, and to identify the type of bleeding and ischemia (decreased blood flow) that may occur in this group of patients. The registry will collect information about physician and patient-related factors that may influence the patterns for prescribing the medications and patient adherence.
The registry will enroll 2500 patients in an “all-comer’s” approach, which means that the inclusion criteria is very wide and there are very few exclusion criteria, so that almost every consecutive PCI patient is enrolled, whenever possible. Patients will be followed for 12 months after PCI procedure. Patients will receive three phone calls from the study personnel for data updates after PCI, 1) at 30 days, 2) at six months and 3) at one year.
All anti-platelet and anti-thrombotic treatment will be directed by the patient’s physician, meaning that participation in the study does not alter the standard-of-care (usual or routine) medication prescriptions that the patient will receive.
|Inclusion/Notes||PCI stent patients who have Atrial fibrillation/flutter (not caused by a valve problem or other reversible causes) with successful PCI (stent) are eligible to be enrolled.|
|Principal Name||Kevin Marzo, MD|
|Contact Name||Wendy Drewes, BSN, RN, CCRC (email@example.com)|